Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Common Equity (2020 - 2025)

Xeris Biopharma Holdings' Common Equity history spans 6 years, with the latest figure at $13.7 million for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 146.22% year-over-year to $13.7 million, compared with a TTM value of $13.7 million through Dec 2025, up 146.22%, and an annual FY2025 reading of $13.7 million, up 146.22% over the prior year.
  • Common Equity for Q4 2025 was $13.7 million at Xeris Biopharma Holdings, up from -$861000.0 in the prior quarter.
  • The five-year high for Common Equity was $96.5 million in Q1 2022, with the low at -$35.1 million in Q1 2025.
  • Average Common Equity over 5 years is $17.0 million, with a median of $8.8 million recorded in 2023.
  • Year-over-year, Common Equity surged 2336.49% in 2022 and then crashed 832.81% in 2024.
  • Tracing XERS's Common Equity over 5 years: stood at $95.2 million in 2021, then tumbled by 52.55% to $45.2 million in 2022, then plummeted by 115.01% to -$6.8 million in 2023, then plummeted by 336.67% to -$29.6 million in 2024, then skyrocketed by 146.22% to $13.7 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Common Equity are $13.7 million (Q4 2025), -$861000.0 (Q3 2025), and -$19.3 million (Q2 2025).